Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Cocarcinogenicity of Foundry Particulates--Interim Report.

Niemeier-RW; Stettler-LE; Mulligan-LT; Rowland-J
NIOSH 1982 Apr:418-444
The cocarcinogenicity of foundry sands with benzo(a)pyrene (50328) (BaP) was investigated and an assessment was made of the cocarcinogenic potential of silica sand substitutes in an animal model. At the same time the fibrogenic activity of these substitutes as compared to a reference quartz (14808607) (Minusil) was considered. The sands tested included Ottawa sand from two samples, chromite sand, olivine sand from two samples, zirconium silicate sand from four samples, aluminum silicate sand from three samples, and control silica sand. Except for the Ottawa sand and the Minusil sand which were primarily quartz, the sands contained less than 1 percent free silica. Olivine samples contained high chromium (7440473) and nickel (7440020) contents and zircon sands contained high concentrations of hafnium (7440586). Fiber analysis indicated that all fibers in the olivine samples were magnesium silicates with some containing small amounts of iron; 58 percent had diffractions patterns of chrysotile (12001295) asbestos. Chromite sand contained about 50 percent chrysotile asbestos fibers. Treatment groups of 6 to 8 week old male Syrian-Golden-hamsters were given either the particulate alone or in combination with 3 milligrams of BaP via intratracheal instillation given weekly for 15 weeks. Groups receiving only the particulates showed survival rates at 15 weeks of 62 to 84 percent with the exception of American Zircon and Washington olivine sands with 56 and 54 percent survival, respectively. Survival for the combined dosed groups ranged from 32 to 68 percent. These figures ranged from 50 to 97 percent of the survival rates with particulate dosing alone. The development of lung tumors appeared to affect survival. Lung tumors were noted in every group receiving the combined treatment. No lung tumors were found in the absence of treatment with BaP.
NIOSH-Contract; Contract-210-79-0036; NIOSH-Author; Mineral-dusts; Pulmonary-system-disorders; Asbestos-dust; Foundries; Laboratory-animals; Carcinogens; Lung-cancer; Silica-dusts;
50-32-8; 14808-60-7; 7440-47-3; 7440-02-0; 7440-58-6; 12001-29-5;
Publication Date
Document Type
Conference/Symposia Proceedings;
Funding Type
Fiscal Year
NTIS Accession No.
NTIS Price
Identifying No.
Priority Area
Asthma and Chronic Obstructive Pulmonary Disease; Disease and Injury; Pulmonary-system-disorders;
Source Name
Proceedings of the Second NCI/EPA/NIOSH Collaborative Workshop: Progress on Joint Environmental and Occupational Cancer Studies, September 9-11, 1981, Rockville, Maryland